PRESS RELEASE published on 05/27/2025 at 14:30, 1 year 5 months ago Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada Formycon and Fresenius Kabi announce commercial launch of FYB202/Otulfi ustekinumab biosimilar in Canada, expanding treatment options for chronic autoimmune diseases Canada Formycon Fresenius Kabi Ustekinumab Biosimilar FYB202/Otulfi
BRIEF published on 05/19/2025 at 15:05, 1 year 6 months ago Formycon and Fresenius Kabi Achieve FDA Interchangeability Approval for FYB202/Otulfi® FDA Approval Biosimilars Formycon Fresenius Kabi Otulfi®
BRIEF published on 05/19/2025 at 15:05, 1 year 6 months ago Formycon et Fresenius Kabi obtiennent l'approbation d'interchangeabilité de la FDA pour FYB202/Otulfi® Approbation De La FDA Formycon Fresenius Kabi Biosimilaires Otulfi®
PRESS RELEASE published on 05/19/2025 at 15:00, 1 year 6 months ago Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz) Formycon and Fresenius Kabi receive FDA approval for interchangeability of FYB202/Otulfi (ustekinumab-aauz) with Stelara, enhancing patient access to treatment options for inflammatory diseases in the US FDA Approval Formycon Fresenius Kabi Biologics Interchangeability
BRIEF published on 05/12/2025 at 06:35, 1 year 6 months ago Formycon Achieves Key Milestones in Q1 2025 Amid Challenging Conditions Strategic Partnerships Financial Guidance Formycon Q1 2025 Biosimilar Approvals FYB202 Launch
BRIEF published on 05/12/2025 at 06:35, 1 year 6 months ago Formycon franchit des étapes clés au premier trimestre 2025 dans des conditions difficiles Partenariats Stratégiques Orientation Financière Formycon T1 2025 Approbations De Biosimilaires Lancement Du FYB202
PRESS RELEASE published on 05/12/2025 at 06:30, 1 year 6 months ago Formycon reports strong operational performance and financial results for first quarter of 2025 Formycon AG reports strong operational performance and financial results for the first quarter of 2025. Market approvals, revenue growth, and strategic partnerships discussed Financial Results Operational Performance Formycon AG Biosimilars Market Approvals
BRIEF published on 05/07/2025 at 09:42, 1 year 6 months ago Formycon Announces Q1 2025 Results Conference and Investor Conferences Investor Conferences Formycon AG Management Board Financial Outlook Q1 2025 Results
BRIEF published on 05/07/2025 at 09:42, 1 year 6 months ago Formycon annonce sa conférence sur les résultats du premier trimestre 2025 et ses conférences avec les investisseurs Conseil D'administration Formycon AG Conférences D'investisseurs Perspectives Financières Résultats Du Premier Trimestre 2025
PRESS RELEASE published on 05/07/2025 at 09:37, 1 year 6 months ago Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences Formycon AG to discuss Q1 2025 results in a conference call and participate in investor conferences. Details and webcast link available. Biosimilar development focus Conference Call Investor Conferences Formycon AG Biosimilars Q1 2025 Results
Published on 11/20/2026 at 02:00, 10 hours 37 minutes ago PPX Mining Announces Completion of Debt Settlement
Published on 11/19/2026 at 23:30, 13 hours 7 minutes ago EQ Inc. Reports Third Quarter 2026 Financial Results
Published on 11/19/2026 at 23:00, 13 hours 37 minutes ago Redwood AI Reports Positive Interim Q-SAFE Findings Supporting Quantum-Assisted Chemical Safety Screening
Published on 11/19/2026 at 22:35, 14 hours 2 minutes ago Pampa Medina Drilling Intersects 102m of 1.0% Cu and 5.1g/t Ag from SPRD-21; 22m of 2.1% Cu and 10g/t Ag from SPRD-18; and 8m of 3.21% Cu and 27.5g/t Ag from SPRD-24
Published on 11/19/2026 at 22:25, 14 hours 12 minutes ago Kidoz Reports Record Nine-Month Revenue of US$9,900,750
Published on 11/20/2026 at 11:29, 1 hour 8 minutes ago REPLOID implements 15-for-1 stock split and moves from auction to continuous trading
Published on 11/20/2026 at 11:05, 1 hour 32 minutes ago BIRKENSTOCK EXPANDS IN THE GREEK MARKET WITH THE OPENING OF TWO NEW RETAIL DESTINATIONS IN ATHENS
Published on 11/20/2026 at 10:59, 1 hour 38 minutes ago EQS-Adhoc: Revenue decreases by approximately 28.6% in the first half of the financial year // Positive revenue and earnings outlook for the 2026/2027 financial year remains unchanged
Published on 11/19/2026 at 19:00, 17 hours 37 minutes ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 19:00, 17 hours 37 minutes ago MR.BRICOLAGE : PERSPECTIVES POUR L'EXERCICE 2026
Published on 11/19/2026 at 08:30, 1 day 4 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing
Published on 11/19/2026 at 08:30, 1 day 4 hours ago Souveraineté des données : Cegedim ouvre EB6, un datacenter nouvelle génération pour l'IA et la haute densité